Research Analyst at Lifesize Capital
Sam Sliski is an equity analyst at Lifesize Capital, specializing in coverage of late-stage biotechnology and pharmaceutical companies including Roivant Sciences. He regularly participates in earnings calls and investor communications with leadership at Roivant, providing in-depth analysis and market sizing on indications such as Graves’ disease. Although specific performance metrics and industry rankings are not publicly disclosed, Sliski is recognized for direct engagement with management teams and detailed sector research. Details regarding his FINRA registration, securities licenses, or prior career history are not publicly available.
Sam Sliski asked for a comparison of the uncontrolled Graves' disease opportunity to the MG market for FcRNs, in terms of market size and potential.
CEO Matthew Gline acknowledged the tremendous MG market but highlighted the large number of uncontrolled Graves' patients, seeing it as an exciting opportunity to build something significant. He plans to discuss the commercial opportunity further on December 11th.
Sam Sliski asked to compare the uncontrolled Graves' disease opportunity with what FcRns have shown in the MG market, in terms of market size and opportunity.
CEO Matt Gline stated it's hard to directly compare with the tremendous MG market but highlighted the many uncontrolled Graves' patients as an exciting opportunity. He mentioned that the commercial opportunity in Graves' disease would be discussed further at the upcoming Investor Day, emphasizing the significant number of patients who could benefit.
Performance on expert-authored financial analysis tasks